TRCT
INMB icon

Tower Research Capital (TRC)’s INmune Bio INMB Stock Holding History

Tower Research Capital (TRC)’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,772
Closed -$13.3K – 5452
2026
Q1 		$13.3K Buy
11,772
+5,860
+99% +$8.35K ﹤0.01% 3752
2025
Q4 		$9.22K Sell
5,912
-692
-10% -$1.24K ﹤0.01% 3913
2025
Q3 		$13.7K Buy
6,604
+4,303
+187% +$9.85K ﹤0.01% 3664
2025
Q2 		$5.32K Buy
2,301
+279
+14% +$2.05K ﹤0.01% 4206
2025
Q1 		$15.8K Sell
2,022
-152
-7% -$1.21K ﹤0.01% 3203
2024
Q4 		$10.2K Sell
2,174
-908
-29% -$4.73K ﹤0.01% 3835
2024
Q3 		$16.6K Buy
+3,082
New +$21.9K ﹤0.01% 3354
2024
Q2 		– Sell
-2,255
Closed -$26.5K – 5839
2024
Q1 		$26.5K Buy
2,255
+721
+47% +$8.71K ﹤0.01% 2754
2023
Q4 		$17.3K Sell
1,534
-1,009
-40% -$8.46K ﹤0.01% 3745
2023
Q3 		$17.2K Buy
2,543
+973
+62% +$8.07K ﹤0.01% 3515
2023
Q2 		$14.3K Sell
1,570
-467
-23% -$3.75K ﹤0.01% 3712
2023
Q1 		$13K Buy
2,037
+534
+36% +$4.3K ﹤0.01% 3976
2022
Q4 		$10K Sell
1,503
-2,406
-62% -$17.1K ﹤0.01% 4016
2022
Q3 		$25K Buy
+3,909
New +$34.3K ﹤0.01% 3756
2022
Q1 		– Sell
-7,306
Closed -$75K – 6306
2021
Q4 		$75K Buy
+7,306
New +$108K ﹤0.01% 2436
2021
Q3 		– Sell
-1,401
Closed -$25K – 5950
2021
Q2 		$25K Sell
1,401
-11,964
-90% -$161K ﹤0.01% 3676
2021
Q1 		$159K Buy
+13,365
New +$241K ﹤0.01% 2194
2020
Q4 		– Sell
-600
Closed -$6K – 5268
2020
Q3 		$6K Sell
600
-755
-56% -$7.68K ﹤0.01% 4289
2020
Q2 		$7K Buy
+1,355
New +$6.83K ﹤0.01% 4149
2019
Q4 		– Sell
-204
Closed -$1K – 3913
2019
Q3 		$1K Buy
+204
New +$1.51K ﹤0.01% 3874

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s INMB Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 11,772 shares — an estimated $13.3K sold.

Tower Research Capital (TRC) first reported a position in INMB in Q3 2019 and held it in 20 quarters. The position peaked at $159K in Q1 2021. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 11,772 INmune Bio shares in Q2 2026, an estimated $13.3K.
  • Tower Research Capital (TRC) first reported a position in INmune Bio in Q3 2019 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s INmune Bio position peaked at $159K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.